[{"id":"9d08cc44-2ff2-4ddf-8a4a-45f9d74b95ce","acronym":"","url":"https://clinicaltrials.gov/study/NCT03319901","created_at":"2021-01-18T16:23:44.923Z","updated_at":"2024-07-02T16:35:00.283Z","phase":"Phase 1/2","brief_title":"Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL","source_id_and_acronym":"NCT03319901","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BCL2","pipe":" | ","alterations":" BCL2 expression • MCL1 expression","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MCL1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax)"],"overall_status":"Recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 10/30/2017","start_date":" 10/30/2017","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2024-05-29"},{"id":"0ddf2dab-b38d-4054-a616-48669cd75157","acronym":"","url":"https://clinicaltrials.gov/study/NCT02143401","created_at":"2021-01-18T09:57:19.810Z","updated_at":"2024-07-02T16:35:01.909Z","phase":"Phase 1","brief_title":"Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors","source_id_and_acronym":"NCT02143401","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MCL1 • AFP • CASP3","pipe":" | ","alterations":" MCL1 expression","tags":["MCL1 • AFP • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MCL1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • navitoclax (ABT 263)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 11/07/2014","start_date":" 11/07/2014","primary_txt":" Primary completion: 11/30/2022","primary_completion_date":" 11/30/2022","study_txt":" Completion: 05/20/2025","study_completion_date":" 05/20/2025","last_update_posted":"2024-05-22"},{"id":"7731b3b2-049a-4507-9d5f-a1c0e3590901","acronym":"","url":"https://clinicaltrials.gov/study/NCT05744739","created_at":"2023-10-18T17:12:49.031Z","updated_at":"2024-07-02T16:35:06.324Z","phase":"Phase 1","brief_title":"Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT05744739","lead_sponsor":"Northwestern University","biomarkers":" MCL1","pipe":" | ","alterations":" MCL1 expression","tags":["MCL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MCL1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tomivosertib (eFT508)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 09/29/2023","start_date":" 09/29/2023","primary_txt":" Primary completion: 04/23/2029","primary_completion_date":" 04/23/2029","study_txt":" Completion: 04/23/2030","study_completion_date":" 04/23/2030","last_update_posted":"2024-05-02"},{"id":"f374dc4d-c613-437c-8a29-943b1442e3ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT01303341","created_at":"2021-01-18T05:18:01.764Z","updated_at":"2024-07-02T16:35:13.428Z","phase":"Phase 1","brief_title":"Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma","source_id_and_acronym":"NCT01303341","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2","pipe":" | ","alterations":" BCL2 expression • MCL1 expression","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MCL1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • riluzole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 02/18/2011","start_date":" 02/18/2011","primary_txt":" Primary completion: 05/01/2012","primary_completion_date":" 05/01/2012","study_txt":" Completion: 09/09/2024","study_completion_date":" 09/09/2024","last_update_posted":"2024-03-21"},{"id":"d694717e-b927-4af3-9e74-7306f9efff05","acronym":"","url":"https://clinicaltrials.gov/study/NCT01188252","created_at":"2021-01-18T04:45:06.986Z","updated_at":"2025-02-25T17:18:29.403Z","phase":"Phase 1","brief_title":"Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies","source_id_and_acronym":"NCT01188252","lead_sponsor":"Bayer","biomarkers":" CASP3 • CDKN1A • ANXA5","pipe":" | ","alterations":" MCL1 expression","tags":["CASP3 • CDKN1A • ANXA5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MCL1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e roniciclib (BAY1000394)"],"overall_status":"Completed","enrollment":" Enrollment 112","initiation":"Initiation: 08/01/2010","start_date":" 08/01/2010","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2017-01-09"}]